This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis
by Zacks Equity Research
Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis
Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
by Zacks Equity Research
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
Allergan (AGN) Presents Positive Data on Glaucoma Candidate
by Zacks Equity Research
Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.
Merck's Keytruda Gets FDA Nod for 2nd Lymphoma Indication
by Zacks Equity Research
Merck's (MRK) Keytruda gets FDA approval for primary mediastinal B-cell lymphoma (PMBCL) - its second label expansion approval this week.
J&J (JNJ) Accepts Platinum Equity's Offer for LifeScan Unit
by Zacks Equity Research
Johnson & Johnson (JNJ) to sell its LifeScan diabetes device unit to Platinum Equity.
Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate
by Zacks Equity Research
Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.
Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study
by Zacks Equity Research
Allergan's (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.
Alzheimer's Research Stumbles Again: What's the Road Ahead?
by Kinjel Shah
The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.
AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.
Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval
by Zacks Equity Research
AbbVie (ABBV) and Roche's (RHHBY) cancer drugs, Venclexta and Rituxan receive approval for combination use in second-line chronic lymphocytic leukemia.
Amgen's (AMGN) Prolia Gets Label Expansion Approval in Europe
by Zacks Equity Research
Amgen (AMGN) announces approval for its regulatory application seeking label expansion for Prolia in Europe.
JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space
by Indrajit Bandyopadhyay
Given the growing interest in JAK-inhibitor based treatments, here's a look at some companies that are looking to change the ways to treat autoimmune diseases.
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie
Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus
by Zacks Equity Research
Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.
J&J Receives Buyout Offer for Sterilization Products Unit
by Zacks Equity Research
Johnson & Johnson (JNJ) receives a binding offer worth $2.8 billion from Fortive Corporation for its sterilization products business.
Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive
by Zacks Equity Research
AbbVie (ABBV) announces positive top-line results from the fifth phase III study on its JAK inhibitor, upadacitinib in moderate-to-severe rheumatoid arthritis.
Merck Presents Positive Melanoma Data on Keytruda at ASCO
by Zacks Equity Research
Merck (MRK) presents encouraging data from two pivotal advanced melanoma studies on its PD-L1 inhibitor, Keytruda.
Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis
by Zacks Equity Research
Eli Lilly (LLY) and its partner Incyte announce approval of their arthritis drug, Olumiant, in the United States. The drug will be available at two-fifth of the price of leading RA drugs.
Merck's (MRK) Keytruda Lung Cancer Data in Focus at ASCO
by Zacks Equity Research
Merck (MRK) presents data from several cancer studies of its PD-L1 inhibitor, Keytruda at ASCO including two key lung cancer trials.
The Zacks Analyst Blog Highlights: Chevron, Wells Fargo, Eli Lilly, FedEx and Valero
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Wells Fargo, Eli Lilly, FedEx and Valero
Allergan Recalls Taytulla Oral Contraceptives, Stock Down
by Zacks Equity Research
Allergan (AGN) recalls some sample packs of Taytulla oral birth control pills. Shares decline.
Novo Nordisk's Oral Ozempic Positive in Diabetes Study
by Zacks Equity Research
Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.
Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval
by Swarup Gupta
The Dow endured another volatile week marked by key geopolitical developments.
FDA Confirms September Action Date for Teva's Migraine Drug
by Zacks Equity Research
Teva (TEVA) confirms that FDA has extended the goal date of the Biologics License Application (BLA) for fremanezumab to September from mid-June.
Merck's Keytruda Shows Survival Benefit in Squamous NSCLC
by Zacks Equity Research
Merck's (MRK) Keytruda in combination with chemotherapy demonstrates better OS and PFS in first-line metastatic squamous NSCLC compared to chemotherapy alone.